A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients

Author： Fu Bo   Lunt Mark   Galloway James   Dixon Will   Hyrich Kimme   Symmons Deborah  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.23, Iss.2, 2013-03, pp. : 461-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 11, 2012-04 ,pp. : 1502-1511

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

By Ranganathan Prabha  

Pharmacogenomics, Vol. 6, Iss. 5, 2005-07 ,pp. : 481-490

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease

By Shetty A.   Forbes A.  

American Journal of PharmacoGenomics, Vol. 2, Iss. 4, 2002-01 ,pp. : 215-221

Adis International

Access to resources Recommend Favorite

Guidelines on the use of anti-tumour necrosis factor (TNF) therapies in patients with rheumatoid arthritis (RA) have been updated

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 475, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Tumor Necrosis Factor-a Blockade in Rheumatoid Arthritis: Responders Vs Non Responders

By  

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 361-368

Bentham Science Publishers

Access to resources Recommend Favorite